⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624020 | 0.94 | — | — | |
| SCHEMBL14865081 | 0.92 | CES2 (0.50) | — | |
| SCHEMBL611777 | 0.92 | CES2 (0.50) | — | |
| SCHEMBL9269248 | 0.92 | CES2 (0.50) | — | |
| SCHEMBL18193512 | 0.92 | CES2 (0.50) | — | |
| SCHEMBL2108161 | 0.92 | CES2 (0.50) | — | |
| SCHEMBL17793354 | 0.92 | CES2 (0.50) | — | |
| SCHEMBL15045494 | 0.89 | NLRP3 (0.37) | — | |
| SCHEMBL16366 | 0.88 | — | — | |
| SCHEMBL18373930 | 0.87 | CES2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398120-B2 | Substituted hydantoinamides as ADAMTS7 antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2025-08-26 | — | — | US | disclosed |
| CN-118239937-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239938-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4058448-B1 | HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| CN-111094233-B | Compounds, compositions, and methods | 戴纳立制药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11851440-B2 | Modulators of eukaryotic initiation factor 2B, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| EP-3523311-B1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030092720-A1 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2003-05-15 | — | — | US | disclosed |
| CN-1284064-A | 2,3-substituted indole compounds as cox-2 inhibitors | PFIZER PHARMA (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |
| WO-1996033181-A1 | ETHYNYLTHIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-10-24 | — | — | WO | disclosed |
| EP-0355353-B1 | Cycloalkylthiazole derivatives | HOFFMANN LA ROCHE (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5001140-A | Cycloalkylthiazoles | HOFFMANN-LA ROCHE INC. (US) | 1991-03-19 | — | — | US | disclosed |
| EP-0355353-A2 | Cycloalkylthiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-02-28 | — | — | EP | disclosed |